With the increase in new therapies to treat cancer, improved diagnostic tools are needed to help determine best treatment options. Many radiopharmaceuticals used with positron-emission tomography/computed tomography have been tested to evaluate solid cancers. Two of the newer radiopharmaceuticals are 18F sodium fluoride and radiolabeled choline. This article reviews these new technologies, providing background and potential clinical use.
At a Glance
- Several new radiotracers have been developed and are being evaluated in clinical oncology practice.
- These new radiopharmaceuticals are being used with positron-emission tomography/computed tomography imaging.
- This new type of imaging may allow for earlier detection of metastases than traditional methods.